JPH02295485A - Extraction of dna - Google Patents
Extraction of dnaInfo
- Publication number
- JPH02295485A JPH02295485A JP11536989A JP11536989A JPH02295485A JP H02295485 A JPH02295485 A JP H02295485A JP 11536989 A JP11536989 A JP 11536989A JP 11536989 A JP11536989 A JP 11536989A JP H02295485 A JPH02295485 A JP H02295485A
- Authority
- JP
- Japan
- Prior art keywords
- leukocyte
- filter
- dna
- white blood
- blood cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000605 extraction Methods 0.000 title claims 2
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 37
- 210000004369 blood Anatomy 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims abstract description 12
- 238000005406 washing Methods 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 7
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 7
- 229920000728 polyester Polymers 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 229920000742 Cotton Polymers 0.000 claims abstract description 3
- 239000004952 Polyamide Substances 0.000 claims abstract description 3
- 229920002647 polyamide Polymers 0.000 claims abstract description 3
- 229920002239 polyacrylonitrile Polymers 0.000 claims abstract 2
- 239000002657 fibrous material Substances 0.000 claims description 7
- 238000007400 DNA extraction Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 230000008014 freezing Effects 0.000 abstract description 5
- 238000007710 freezing Methods 0.000 abstract description 5
- 238000010257 thawing Methods 0.000 abstract description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract description 3
- QHQZEEGNGSZBOL-UHFFFAOYSA-N 2-(aminomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-N 0.000 abstract description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract description 2
- 229960002897 heparin Drugs 0.000 abstract description 2
- 229920000669 heparin Polymers 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 2
- 230000003544 deproteinization Effects 0.000 abstract 1
- 239000012266 salt solution Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 7
- 229920001917 Ficoll Polymers 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〈産業上の利用分野〉
本発明はサザン・ハイブリダイゼーシッン(South
ern hybridization)などに用いる白
血球DNAを抽出するための効率的なDNAの抽出方法
に関するものである.
く従来の技術〉
近年、遺伝子操作技術の目覚ましい発展により種々の疾
患を遺伝子レベルで解析することが可能になりつつある
。たとえば末梢血管から採取された血液の白血球から複
雑な方法でゲノムDNAを抽出した後、サザン・ハイブ
リダイゼーシヲンなどの手法を用いて解析し、遺伝疾患
などの診断を行うなどである.
サザン・ハイブリダイゼーシッン法は、細胞(白血球、
リンパ球)からDNAを抽出した後、制限酵素を用いて
DNAを切断し、この切断されたDNAを電気泳動した
後メンプランフィルタに移し(プロッティングという)
、それからメンブランフィルタを軽く洗浄した後オーブ
ンで乾燥させ、好ましくはフィルタの非特異吸着を減少
させる操作を行った後、31Pで標識した変性プローブ
DNAを加えてハイブリダイゼーションを行い、これを
洗浄してオートラジオグラフィーでプロウィルスDNA
や遺伝子の欠損、変異等の多型を検出するものであり、
従来、DNAは一般にフィコル法(Ficoll )に
よって分離された白血球から抽出されていた。[Detailed Description of the Invention] <Industrial Application Field> The present invention is applicable to southern hybridization.
The present invention relates to an efficient DNA extraction method for extracting white blood cell DNA for use in, for example, ern hybridization. Background Art> In recent years, with the remarkable development of genetic manipulation technology, it has become possible to analyze various diseases at the genetic level. For example, genomic DNA is extracted from white blood cells in blood collected from peripheral blood vessels using a complicated method, and then analyzed using techniques such as Southern hybridization to diagnose genetic diseases. The Southern hybridization method uses cells (white blood cells, white blood cells,
After extracting DNA from lymphocytes, the DNA is cut using restriction enzymes, the cut DNA is electrophoresed, and then transferred to a membrane filter (referred to as plotting).
Then, after lightly washing the membrane filter and drying it in an oven, preferably performing an operation to reduce non-specific adsorption of the filter, hybridization is performed by adding 31P-labeled denatured probe DNA, and this is washed. Proviral DNA by autoradiography
It detects polymorphisms such as genetic defects, mutations, etc.
Traditionally, DNA has generally been extracted from leukocytes separated by the Ficoll method.
しかしながら、上記フィコル法は、[ヘパリンなどの抗
凝固剤を添加した血液に等量のリン酸緩衝食塩t& (
P B S, P H7.4 )を加えて良《混和し、
これを分離剤を収容したスピッツ管に静かに注入して、
稀釈した血液試料を分離剤の上に重層し、400g30
分遠心した後、白血球を含む中間層を掻き乱さぬよう上
層を取り除き、さらに上下層を若干含む中間層を採取し
てこれを別のスピッツ管に採りPBSを加えて混和し洗
浄を行い、これを今度は160glo分遠心し、さらに
、上滑を取り除きPBSを加えて混和し100glO分
遠心するという操作を2回繰り返した後、上清を取り除
き必要とする溶媒に浮遊させ、最後に顕!鏡で数を算定
し、白血球の数を必要数に調整する。」というものであ
り、操作が非常に煩雑であり、また操作者の熟練を要す
るものであった.く発明の解決しようとする課題〉
本発明は如上の事情に鑑みてなされたもので、操作が簡
単で、熟練を要せず、かつ効率のよいDNAの抽出方法
を提供することを目的とする。However, the above-mentioned Ficoll method requires that blood to which an anticoagulant such as heparin has been added is mixed with an equal amount of phosphate-buffered saline t & (
Add P B S, P H7.4) and mix well.
Gently inject this into the Spitz tube containing the separating agent,
The diluted blood sample was layered on top of the separating agent, and 400g30
After centrifugation, remove the upper layer without disturbing the intermediate layer containing white blood cells, collect the intermediate layer containing a small amount of the upper and lower layers, transfer it to another Spitz tube, add PBS, mix and wash. This time, centrifuge for 160glO, then remove the supernatant, add PBS, mix, and centrifuge for 100glO twice.Then, remove the supernatant and suspend in the required solvent.Finally, visualize! Calculate the number using a mirror and adjust the number of white blood cells to the required number. '', the operation was extremely complicated and required the operator's skill. Problems to be Solved by the Invention The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a method for extracting DNA that is easy to operate, does not require skill, and is efficient. .
〈課題を解決するための手段〉
本発明は上記の課題を解決するために、(ア)平均直径
10lIm以下の繊維状物質が容器に充填されてなるフ
ィルタを用いて、血液から白血球を吸着分離する.(イ
)前記フィルタに吸着された白血球を洗浄液で洗浄して
、ヘモグロビン等の蛋白質を除去する。(ウ)該白血球
をマイナス20℃以下の低温でフィルタごと凍結した後
、室温で解凍する.の各工程を含んでなるDNAの抽出
方法を採用している.
く作用〉
本発明によれば、フィルタに血液を通すと、血液中の白
血球は殆ど繊維状物質に吸着され、血液の他の成分と分
離される。このフィルタに洗浄液の例えばTE(10m
Mトリス〔ヒドロキシメチル〕アミノエタン、1mM
EDTA,PH7.6)を通して洗浄すると、ヘモグ
ロビン等の蛋白質が除去される。こうして分離洗浄され
た白血球をフィルタごと例えば−80℃で凍結した後、
室温で放置して白血球を解凍する.それから繊維状物質
にTE−+*ix (TE,1 0mM Na c
L 1.5 mM Mgc lx 、PH7.5 )
を加えると、フィルタの繊維状物質に吸着されていた白
血球は繊維状物賞から容易に回収される。<Means for Solving the Problems> In order to solve the above problems, the present invention (a) adsorbs and separates leukocytes from blood using a filter in which a container is filled with a fibrous substance having an average diameter of 10 lIm or less; do. (b) The white blood cells adsorbed on the filter are washed with a washing solution to remove proteins such as hemoglobin. (c) Freeze the leukocytes together with the filter at a low temperature of -20°C or lower, and then thaw at room temperature. We use a DNA extraction method that includes each step of the following steps. Effect> According to the present invention, when blood is passed through the filter, most of the white blood cells in the blood are adsorbed to the fibrous substance and separated from other blood components. Washing liquid such as TE (10 m
M tris[hydroxymethyl]aminoethane, 1mM
Washing through EDTA, pH 7.6) removes proteins such as hemoglobin. After freezing the white blood cells thus separated and washed together with the filter at, for example, -80°C,
Thaw the white blood cells by leaving at room temperature. The fibrous material was then treated with TE-+*ix (TE, 10mM Na c
L 1.5mM Mgclx, PH7.5)
When added, the white blood cells adsorbed to the fibrous material of the filter can be easily recovered from the fibrous material.
回収された白血球からゲノムDNAを抽出する操作は、
周知の方法で行うことが出来る.く実施例〉
次に本発明の実施例について説明する。The procedure for extracting genomic DNA from collected white blood cells is as follows:
This can be done using a well-known method. Embodiments Next, embodiments of the present invention will be described.
本発明のDNAの抽出方法は、(ア)平均直径10μm
以下の繊維状物質が容器に充填されてなるフィルタを用
いて、血液から白血球を吸着分離する。(イ)前記フィ
ルタに吸着された白血球を洗浄液で洗浄して、ヘモグロ
ビン等の蛋白質を除去する.(ウ)該白血球をマイナス
20℃以下の低温でフィルタごと凍結した後、室温で解
凍する.の各工程を含んでなるものであり、白血球解凍
後、フィルタから繊維状物賞を取り出し、これにたとえ
ばT E−vixなどの緩衝液を加えて白血球をたとえ
ばスピッツ管など適宜の試験管に回収し、更にこれにた
とえば10%硫酸ドデシルナトリウム(SDS)などの
界面活性剤と蛋白分解酵素(Protein ase
K )を加えて、65℃で15時間インキエベートし、
これに熱処理したRNA分解酵素(RNaseA)を加
えて37℃で1時間インキエベートする.それからこれ
をフェノール試薬で処理し、DNAをエタノールで沈澱
させ精製するものである.蛋白分解酵素を加えるのは、
DNAを包んでいる細胞の蛋白質やDNAをつなぎ合わ
せるための蛋白質(ヒストン等)を分解するためであり
、またRNaseAを加えるのは、RNAとDNAの親
和力の方がDNAとDNAのそれより大なためにRNA
がDNAに混じるとハイプリダイゼーションを行った時
にプローブDNAに対する阻害作用を示すことがあるか
らである。The DNA extraction method of the present invention includes (a) an average diameter of 10 μm;
White blood cells are adsorbed and separated from blood using a filter whose container is filled with the following fibrous material. (b) The white blood cells adsorbed on the filter are washed with a washing solution to remove proteins such as hemoglobin. (c) Freeze the leukocytes together with the filter at a low temperature of -20°C or lower, and then thaw at room temperature. After thawing the white blood cells, the fibrous material is removed from the filter, a buffer such as TE-vix is added thereto, and the white blood cells are collected into a suitable test tube such as a Spitz tube. Furthermore, a surfactant such as 10% sodium dodecyl sulfate (SDS) and a proteinase are added to this.
K) and incubate at 65°C for 15 hours.
Add heat-treated RNA degrading enzyme (RNase A) to this and incubate at 37°C for 1 hour. This is then treated with a phenol reagent, and the DNA is purified by precipitation with ethanol. Adding proteolytic enzymes is
The reason for adding RNase A is to degrade cellular proteins that wrap DNA and proteins that connect DNA together (such as histones). for RNA
This is because if mixed with DNA, it may exhibit an inhibitory effect on probe DNA during hybridization.
繊維状物質としては、ポリエステルやボリアミド、綿、
ポリアクリル二トリルが使用可能であり、特にポリエス
テルが白血球回収率が高く好ましい。繊維状物質を充填
する容器は、m液を流入させ排出させることのできる開
口を存するものであり、たとえば注射器や市販の白血球
除去フィルタのケースなどが挙げられる。フィルタに吸
着された白血球を洗浄するための洗浄液は、繊維状物質
に付着したヘモグロビン等の蛋白質を除去するためのも
ので、−SにTEが使用される.白血球の凍結温度は、
マイナス2 ”C以下であり、好ましくはマイナス20
℃以下が良く、特にマイナス80℃前後が良い.マイナ
ス80℃前後で急速に冷凍した方が細胞を傷めないで済
むからである。Fibrous materials include polyester, polyamide, cotton,
Polyacrylic nitrile can be used, and polyester is particularly preferred since it has a high leukocyte recovery rate. The container filled with the fibrous substance has an opening through which the m-liquid can flow in and be discharged, and includes, for example, a syringe and a case of a commercially available leukocyte removal filter. A cleaning solution for cleaning white blood cells adsorbed on the filter is used to remove proteins such as hemoglobin attached to fibrous substances, and TE is used for -S. The freezing temperature of white blood cells is
Minus 2”C or less, preferably minus 20
Temperatures below ℃ are best, especially around minus 80℃. This is because rapid freezing at around -80°C will not damage the cells.
尚、室温で放1して解凍するのはフィルタから白血球が
剥がれやすくするためであり、解凍後の緩衝液は細胞に
害を与えずPHを一定に保つものが使用され、一般にT
E−mjxが使用される。TEの構成要素としてED
TAが加えられているのは、2価の陽イオンをEDTA
で吸収することにより、2価の陽イオンと結合し易いD
NA分解酵素(DNAase )の反応を阻害するため
である.る.
界面活性剤は白血球を溶解するためのものであり、これ
を加えると白血球は速やかに溶解して内部のDNAなど
が出るため溶液は粘稠になる。界面活性剤は非イオン系
のもので生化学的に使用されるものであれば良く、SD
Sの他にNP−4 0やトウイーン(Twe e n)
等も使用可能である。白血球の回収には緩衝液と界面活
性剤をミックスしたものを用いても良く、また細胞の溶
解には界面活性剤を蛋白分解酵素とミックスして用いて
も良い.
尚、解凍後の白血球の回収以降の操作については、たと
えば雑誌「臨床検査J ( VO1.32 no.4
1988年4月)の第393頁左欄、第4〜37行に紹
介された方法など、適宜の方法が選択可能であ〔実施例
1〕
試験管にヘパリン血(血液9.5−にヘパリン0,5I
I1を加えたもの)をloIri採り、これに生理食塩
水10dを加えたものを用意し、これを容量lOdの注
射器に平均直径3.5μmのポリエステル繊維80■充
填してなるフィルタに、ペリスタポンプ(ダイアル目盛
3)で引きながら流し込み、白血球をポリエステル繊維
に吸着させた。次に注射器内の血液を排出して、ポリエ
ステル繊維に付着しているヘモグロビン等の蛋白1[−
TE10d(4〜IOdの任意量で洗浄できる)で洗浄
して除去した。次いで白血球を注射器ごと−80’Cで
凍結したのち、これを室温で放置して解凍した。The reason why the white blood cells are left to thaw at room temperature is to make it easier for the white blood cells to peel off from the filter, and the buffer used after thawing is one that does not harm the cells and maintains a constant pH.
E-mjx is used. ED as a component of TE
TA is added to divalent cations by EDTA.
D, which easily binds to divalent cations by absorbing
This is to inhibit the reaction of NA degrading enzyme (DNAase). Ru. A surfactant is used to dissolve white blood cells, and when it is added, the white blood cells are quickly dissolved and internal DNA comes out, making the solution viscous. The surfactant may be non-ionic and biochemically used, and SD
In addition to S, NP-4 0 and Tween
etc. can also be used. A mixture of buffer and surfactant may be used to collect leukocytes, and a mixture of surfactant and protease may be used to lyse cells. Regarding the operations after collection of white blood cells after thawing, for example, please refer to the magazine "Clinical Examination J (VO1.32 no.4)
An appropriate method can be selected, such as the method introduced on page 393, left column, lines 4 to 37 of April 1988. 0,5I
10 d of physiological saline was added to this, and a peristaltic pump ( The white blood cells were adsorbed onto the polyester fibers by pouring the mixture while pulling it with the dial scale 3). Next, drain the blood in the syringe and remove the proteins such as hemoglobin attached to the polyester fibers.
It was removed by washing with TE10d (washing can be done with any amount of 4 to IOd). Next, the leukocytes were frozen together with the syringe at -80'C, and then allowed to stand at room temperature to thaw.
それからポリエステル繊維を注射器から取り出し、これ
にT E −mix 4 mlを加えて白血球を洗い出
し回収した.次いで回収された白血球に1o%SDS2
00ul,’lli自分解酵素50μg(5mg/d)
を加え65℃で15時間インキユベートした.そしてさ
らにこれに熱処理したRNA分解酵素3d (1 0*
/d)を加え、37℃で1時間インキユベートし、これ
をフェノール試薬で処理し、エタノールで白血球を沈澱
させDNAを精製した第1表は血液をフィルタに通す前
と通した後の血液中の白血球の量を測定した結果を示す
.約93%の白血球が吸着分離されたことが分かる。Then, the polyester fiber was taken out from the syringe, 4 ml of TE-mix was added thereto, and white blood cells were washed out and collected. The collected leukocytes were then treated with 10% SDS2.
00ul,'lli autolytic enzyme 50μg (5mg/d)
was added and incubated at 65°C for 15 hours. This was further heat-treated with RNA degrading enzyme 3d (1 0 *
/d), incubated at 37°C for 1 hour, treated with phenol reagent, white blood cells precipitated with ethanol, and DNA purified. The results of measuring the amount of white blood cells are shown. It can be seen that about 93% of leukocytes were adsorbed and separated.
また図1はエタノール沈澱後、蒸留水にDNAを溶解さ
せ吸光度を測定した結果を示す。フイコール・ハイバー
ク(ファルマシア社製)を用いてDNAを回収(Fic
oll法)した時とほぼ同様のバクーンを示しており、
DNAが回収されていることが分かる.吸光係数はIO
D−50■/Idであり、DNAは波長260nmのと
ころに現れるがら、本法を用いた場合のDNAの回収量
は33.5■/dであり、Picoll法を用いた場合
(5.6 Ilg/一よりも多い。Moreover, FIG. 1 shows the results of dissolving DNA in distilled water after ethanol precipitation and measuring the absorbance. DNA was recovered using Fichol High Bark (manufactured by Pharmacia) (Fic
It shows almost the same Bakun as when using the oll method),
It can be seen that DNA has been recovered. The extinction coefficient is IO
Although DNA appears at a wavelength of 260 nm, the amount of DNA recovered using this method is 33.5 ■/d, and when using the Picoll method (5.6 Ilg/More than one.
(以下余白)
第1表
〔実施例2〕
本法により回収された白血球がサザン・ハイブリダイゼ
ーシヲンに使用可能であることを11認するために、本
法およびFicol法を用いて抽出したDNAを制限酵
素By,9Iで消化し、甲状腺刺激ホルモンのβ鎖をコ
ードする遺伝子をブロープ(約500bp)としてハイ
ブリダイゼーシツンを試みた.その結果得られたオート
ラジオダラムを第2図および第3図に示す.
本法、Ficol法ともに、4.4kb付近に一木のバ
ンドが見られた。このことから、本法を用いて抽出した
DNAもFicol法を用いて抽出したDNAと同様に
、実際の分析に使用可能であることが分かる.
尚、本法で用いたフィルタは実施例1におけるものと同
じものである。また、プローブの標識はα(”P)一α
CTPを用い、二ックトランスレーション法を用いた。(Margins below) Table 1 [Example 2] In order to confirm that leukocytes recovered by this method can be used for Southern hybridization, DNA extracted using this method and Ficol method. was digested with the restriction enzyme By,9I, and hybridization was attempted using the gene encoding the β chain of thyroid stimulating hormone as a probe (approximately 500 bp). The resulting autoradio durums are shown in Figures 2 and 3. In both this method and the Ficol method, a single band was observed around 4.4 kb. This shows that DNA extracted using this method can be used for actual analysis in the same way as DNA extracted using the Ficol method. Note that the filter used in this method is the same as that in Example 1. In addition, the probe label is α(”P)-α
CTP was used and the dic translation method was used.
〈発明の効果〉
本発明によれば、次のような効果を奏することが出来る
。<Effects of the Invention> According to the present invention, the following effects can be achieved.
(1)白血球を繊維状物質に吸着分離してこれを洗浄し
回収するものなので、操作が簡単であり、また白血球の
純度も高い。(1) Since leukocytes are adsorbed and separated onto a fibrous substance and then washed and recovered, the operation is simple and the purity of the leukocytes is high.
(2)白血球を凍結後これを室温で解凍しているので、
繊維状物質の吸着能が殆ど無くなっており、吸着された
白血球の略全景を容易にかつ効率的に回収することがで
のる.
(3)純度の高い白血球を容易にしかも効率良く回収す
ることができるので、DNAの抽出も容易かつ効率的に
行うことができる。(2) Since the white blood cells are frozen and then thawed at room temperature,
The ability to adsorb fibrous substances is almost completely eliminated, making it possible to easily and efficiently recover almost the entire adsorbed white blood cells. (3) Since highly pure leukocytes can be easily and efficiently collected, DNA extraction can also be performed easily and efficiently.
第1図は本発明の方法とFicoll法により回収され
たDNAの吸光度を示すグラフであり、図中一〇一は本
法を用いた場合、一八ーはFicoll法を用いた場合
である.また、第2図はB,,Q+によって消化された
DNAのパターンを示すオートラジオダラム、第3図は
第2図のDおよび巳を説明するための図である.第1図
Hll 2!11 126 24@ 250
16@ 276 2@0 21@ コSO彼
畏(n耐
弟
図
臼
D
A : Ficoll法
B:本法
C:マーカー
手
続
ネ甫
正
書(方式)
(男1紙)FIG. 1 is a graph showing the absorbance of DNA recovered by the method of the present invention and the Ficoll method, where 101 indicates the case when the present method was used, and 18- indicates the case when the Ficoll method was used. Moreover, FIG. 2 is an autoradiodrum showing the pattern of DNA digested by B, Q+, and FIG. 3 is a diagram for explaining D and Sn in FIG. Figure 1 Hll 2!11 126 24 @ 250
16@ 276 2@0 21@ KoSO Hehi (n Taiyozuzusu D A: Ficoll method B: This method C: Marker procedure nefu seisho (method) (man 1 paper)
Claims (1)
充填されてなるフィルタを用いて、血液から白血球を吸
着分離する。 (イ)前記フィルタに吸着された白血球を洗浄液で洗浄
して、ヘモグロビン等の蛋白質を除去する。 (ウ)該白血球をマイナス20℃以下の低温でフィルタ
ごと凍結した後、室温で解凍する。 の各工程を含んでなるDNAの抽出方法。 2)繊維状物質がポリエステル、ポリアミド、綿、また
はポリアクリロニトリルからなる請求項1記載のDNA
の抽出方法。 3)洗浄液がTEである請求項2記載のDNAの抽出方
法。[Claims] 1) (a) White blood cells are adsorbed and separated from blood using a filter in which a container is filled with a fibrous substance having an average diameter of 10 μm or less. (b) The white blood cells adsorbed on the filter are washed with a washing solution to remove proteins such as hemoglobin. (c) The leukocytes are frozen together with the filter at a low temperature of -20°C or lower, and then thawed at room temperature. A DNA extraction method comprising the steps of: 2) The DNA according to claim 1, wherein the fibrous material is made of polyester, polyamide, cotton, or polyacrylonitrile.
extraction method. 3) The method for extracting DNA according to claim 2, wherein the washing liquid is TE.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11536989A JPH0824583B2 (en) | 1989-05-09 | 1989-05-09 | DNA extraction method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11536989A JPH0824583B2 (en) | 1989-05-09 | 1989-05-09 | DNA extraction method |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02295485A true JPH02295485A (en) | 1990-12-06 |
JPH0824583B2 JPH0824583B2 (en) | 1996-03-13 |
Family
ID=14660824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11536989A Expired - Fee Related JPH0824583B2 (en) | 1989-05-09 | 1989-05-09 | DNA extraction method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0824583B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6383783B1 (en) | 1999-09-21 | 2002-05-07 | 3M Innovative Properties Company | Nucleic acid isolation by adhering to hydrophobic solid phase and removing with nonionic surfactant |
WO2003006650A1 (en) * | 2001-07-09 | 2003-01-23 | Asahi Kasei Kabushiki Kaisha | Method of purifying nucleic acid using nonwoven fabric and detection method |
EP1504121A2 (en) * | 2002-04-24 | 2005-02-09 | Hitachi Chemical Research Center, Inc. | Device and method for high-throughput quantification of mrna from whole blood |
-
1989
- 1989-05-09 JP JP11536989A patent/JPH0824583B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6383783B1 (en) | 1999-09-21 | 2002-05-07 | 3M Innovative Properties Company | Nucleic acid isolation by adhering to hydrophobic solid phase and removing with nonionic surfactant |
WO2003006650A1 (en) * | 2001-07-09 | 2003-01-23 | Asahi Kasei Kabushiki Kaisha | Method of purifying nucleic acid using nonwoven fabric and detection method |
EP1504121A2 (en) * | 2002-04-24 | 2005-02-09 | Hitachi Chemical Research Center, Inc. | Device and method for high-throughput quantification of mrna from whole blood |
EP1504121A4 (en) * | 2002-04-24 | 2005-06-29 | Hitachi Chemical Res Ct Inc | Device and method for high-throughput quantification of mrna from whole blood |
Also Published As
Publication number | Publication date |
---|---|
JPH0824583B2 (en) | 1996-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sharma et al. | “The FSGS Factor”: Enrichment and: in Vivo: Effect of Activity from Focal Segmental Glomerulosclerosis Plasma | |
Keilin et al. | Activity of the cytochrome system in heart muscle preparations | |
JP5253451B2 (en) | Materials and methods for capturing pathogens from samples and removing aurintricarboxylic acid | |
Lenard | Rapid and effective removal of sodium dodecyl sulfate from proteins | |
CN104017800B (en) | Whole genome DNA (Deoxyribonucleic Acid) extraction kit for blood and method thereof | |
CA2160531C (en) | Process for purifying collagenase | |
CN105925564B (en) | The method for extracting plant genome DNA | |
CN108949747A (en) | A kind of kit and application method extracting RNA | |
Thomas Jr et al. | The separation of DNA segments attached to proteins | |
JPS5837561A (en) | Standard or check substance for measuring glycocylating or total haemoglobin | |
CN107904229A (en) | Genome DNA extracting method and extracts kit | |
JPH01294697A (en) | Concentrate of coagulation factors ii, vii, ix and it preparation and use | |
JPH02295485A (en) | Extraction of dna | |
CN103884549A (en) | Sputum cell treatment liquid and application thereof | |
TW201114467A (en) | Method, agent, and kit for isolating nucleic acids | |
Bertani et al. | Focal segmental membranous glomerulonephropathy associated with other glomerular diseases | |
CN116376896A (en) | Kit for extracting plasma free DNA, preparation method and extraction method | |
CN102229927A (en) | Method and reagent for improving rate of extraction of DNAs of castoff cells in case trace sample | |
CN101985461A (en) | Method for extracting total proteins from formaldehyde-fixed tissues or formaldehyde-fixed paraffin-embedded tissues | |
Wolf et al. | Isolation and characterization of dipeptidyl aminopeptidase IV from human kidney cortex | |
CN104498464A (en) | Method for extracting agkistrodon snake venom hemocoagulase from gloydius blomhoffi brevicaudus venom | |
CN108660125A (en) | A method of extracting neutrophil leucocyte azurophilic granule in transfusing blood waste from human body | |
GB1581472A (en) | Compounds of the plasminogen type processes for their production and pharmaceutical compositions containing them | |
Afford et al. | Concentration of bronchoalveolar lavage fluid by ultrafiltration: evidence of differential protein loss and functional inactivation of proteinase inhibitors | |
Hurt et al. | Human Antihemophilic Factor (AHF) Purification A Comparison of Two Procedures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |